New laser zaps eye pressure in seconds for glaucoma patients
NCT ID NCT07281391
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new laser treatment called Direct Selective Laser Trabeculoplasty (DSLT) for people with pigmentary glaucoma, a type of glaucoma that can lead to vision loss. The laser is applied directly through the eye's surface in just a few seconds, aiming to lower high eye pressure. Researchers will follow 45 adults for up to 12 months to see how well the treatment works and if it reduces the need for glaucoma medications.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Direct Selective Laser Trabeculoplasty (DSLT) device
- What this could lead to
- If successful, DSLT could offer a quick, non-invasive way to lower eye pressure in pigmentary glaucoma, potentially reducing the need for daily eye drops.
- What could go wrong
- This is a small, early study with only 45 participants and no comparison group. The results may not apply to all patients, and the pressure-lowering effect might not last long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PIGMENTARY DISPERSION GLAUCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mann Eye Institute
RECRUITINGHouston, Texas, 76134-2099, United States